Joseph W. Arico Ph.D.
Associate | Boston
Joseph W. Arico Ph.D.

Joseph W. Arico, Ph.D. focuses his practice on patent prosecution and counseling in pharmaceuticals and biotechnology. He assists pharmaceutical and biotechnology companies from the startup through post-approval stages in developing robust patent portfolios and strategies. His areas of particular expertise include drafting and prosecuting both U.S. and international patent applications involving active pharmaceutical ingredients, prodrugs, salt forms and polymorphs, formulations, methods of use, and manufacturing syntheses; conducting freedom-to-operate, patentability, validity, and infringement analyses; and performing IP due diligence in connection with in-licensing and acquisition opportunities.

Dr. Arico draws on his nearly 20 years of post-graduate chemistry and pharmaceutical patent law experience to assist clients in developing and executing their patent strategies across the spectrum of pharmaceutical innovation. This includes novel small molecules, heterobifunctional molecules, peptides, oligonucleotides, prodrugs, rescued and repurposed drugs, methods of treating diseases, polymorphs, salt forms and cocrystals, formulations, clinical-stage patient populations and dosing, pharmacokinetics, active pharmaceutical ingredient manufacturing methods, and medical devices. Dr. Arico routinely advises clients on various aspects of pharmaceutical life-cycle management such as loss of exclusivity (LOE) analyses, Orange Book listing, Patent Term Adjustment (PTA), and Patent Term Extension (PTE).

Prior to Dr. Arico’s legal career, he was a postdoctoral fellow at the University of Notre Dame, where his research included the total synthesis of Tolypothrix polyethers and analogs of neopeltolide and epothilone natural products. Dr. Arico earned his Ph.D. at Boston College where he synthesized and studied 3-deazapurine nucleoside analogs and developed glycosylation methodologies.

In 2023, Dr. Arico was recognized as a Rising Star by Super Lawyers in their intellectual property category. 

  • Ipsen Pharmaceuticals in various patent prosecution and Orange Book patent strategy matters relating to Tazverik® (tazemetostat).
  • Nimbus Therapeutics in various patent prosecution and IP diligence matters culminating in Takeda’s acquisition of NDI-034858 (TAK-279; Zasocitinib), its small molecule TKY2 inhibitor, for US$6 billion in cash and commercial milestone payments.
  • X4 Pharmaceuticals in various patent prosecution and counseling matters since its inception in 2015; for example, in maximizing patent and regulatory exclusivities for its CXCR4 inhibitor, mavorixafor (X4P-001), which is a rescued drug currently in Phase 3 clinical trials for the orphan disease WHIM syndrome.
  • Royalty Pharma in various validity and LOE analyses, including in relation to its US$827 million acquisition of Ligand Pharmaceuticals’ royalties on sales of Promacta® (eltrombopag).
  • Pharnext in U.S. patent prosecution and counseling matters relating to PXT3003, a combination of three known small molecule drugs that is in Phase 3 clinical trials for a rare genetic disease.
Services Industries
    • University of Notre Dame, B.S., Chemistry, 2004, cum laude
    • Boston College, Ph.D., Organic Chemistry, 2010
    • Suffolk University Law School, J.D., Intellectual Property Concentration, 2018
    • Massachusetts
    • United States Patent and Trademark Office
    • English
    • Spanish
    • 2020 Pro Bono High Honor Roll, Supreme Judicial Court of Massachusetts (awarded to individual attorneys who complete at least 100 hours of pro bono service during the previous year)
    • American Bar Association
    • American Intellectual Property Association